MEDICAL DEVICE SOFTWARE FOR GENOMICS: REGULATORY FRAMEWORK AND LEGAL LIABILITY

1. INTRODUCTION

Medical Device Software for Genomics Regulation Law concerns the legal control, approval, clinical validation, manufacturing, distribution, and monitoring of software designed to analyse genetic information for medical purposes. Such software includes artificial intelligence (AI) genomic interpretation platforms, DNA sequencing analysis systems, mutation-detection applications, hereditary disease prediction tools, pharmacogenomic decision-support systems, and software used to identify cancer-associated genetic variations.

These technologies can influence diagnosis, treatment selection, reproductive decisions, and preventive healthcare. Incorrect genomic interpretation may result in misdiagnosis, unnecessary treatment, inappropriate medication, or failure to identify serious inherited diseases.

India does not have a separate statute exclusively governing genomic medical-device software. Instead, such products are regulated through the Drugs and Cosmetics Act, 1940, Medical Devices Rules, 2017, applicable in-vitro diagnostic requirements, data-protection legislation, and clinical research standards.

2. LEGAL AND REGULATORY FRAMEWORK IN INDIA

A. DRUGS AND COSMETICS ACT, 1940

The Act provides the principal statutory foundation for regulating medical devices and in-vitro diagnostic products in India. Software intended for medical diagnosis, disease monitoring, or therapeutic decision-making may fall within the medical-device definition.

B. MEDICAL DEVICES RULES, 2017

The Medical Devices Rules establish requirements relating to:

Classification of medical devices according to risk.

Manufacturing and import licences.

Clinical investigations and performance evaluations.

Quality-management systems.

Labelling and technical documentation.

Post-market surveillance and adverse-event reporting.

Software is classified according to its intended medical purpose and associated risks. The four principal risk categories are Class A, Class B, Class C, and Class D.

C. IN-VITRO DIAGNOSTIC REGULATION

Genomic interpretation software connected with DNA sequencing instruments or diagnostic testing may qualify as in-vitro diagnostic medical-device software. Its performance must be supported by appropriate scientific and analytical evidence.

The CDSCO regulates relevant IVD licensing and classification requirements.

D. CDSCO MEDICAL DEVICE SOFTWARE GUIDANCE, 2026

CDSCO issued its Guidance Document on Medical Device Software under MDR-2017 on 21 July 2026. It provides regulatory guidance concerning medical-device software, including IVD software, clinical evidence, intended use, and regulatory compliance. The document operates within the existing statutory framework rather than creating an independent software-regulation statute.

3. CLINICAL VALIDATION AND TECHNICAL REQUIREMENTS

Genomic medical-device software must demonstrate that its intended medical functions are scientifically reliable.

A. ANALYTICAL VALIDATION

Manufacturers should establish:

Accuracy of genetic-variant identification.

Precision and reproducibility of results.

Sensitivity and specificity.

Reliability of sequencing-data interpretation.

Compatibility with relevant genomic reference databases.

Performance across appropriately representative populations.

B. CLINICAL VALIDATION

Clinical validation must establish whether software outputs are clinically meaningful for the intended patient population. For example, a hereditary cancer-risk prediction platform should demonstrate that its predictions are supported by appropriate clinical evidence.

C. ARTIFICIAL INTELLIGENCE VALIDATION

AI-based genomic software should undergo testing for algorithmic bias, data quality, reproducibility, model drift, and reliability across different demographic populations.

Manufacturers should maintain version histories, validation records, cybersecurity controls, and documented procedures for software updates.

4. GENOMIC DATA PROTECTION AND PATIENT CONSENT

Genomic information can reveal inherited disease risks and information about biological relatives. Accordingly, manufacturers and healthcare institutions must establish appropriate safeguards.

The Digital Personal Data Protection Act, 2023, and applicable rules govern relevant digital personal-data processing, subject to their commencement and applicability.

Important compliance obligations include:

Lawful processing of personal genomic information.

Appropriate notice and consent where required.

Reasonable security safeguards.

Access controls and secure data storage.

Restrictions on unauthorised disclosure.

Appropriate retention and deletion procedures.

Transparency concerning secondary research and commercial use.

Genomic data must not be used for unrelated commercial profiling without an appropriate legal basis.5. CLINICAL INVESTIGATION AND REGULATORY APPROVAL

Before commercial deployment, manufacturers must determine whether the software requires medical-device licensing, clinical investigation, or IVD performance evaluation.

Important requirements include:

Preparation of a clinical evaluation report.

Evidence supporting intended diagnostic performance.

Ethics committee approval wherever human clinical research is involved.

Compliance with Good Clinical Practice where applicable.

Documented risk-management procedures.

Secure maintenance of clinical and genomic datasets.

Regulatory approval for applicable manufacturing and import activities.

Software developers must distinguish research-use-only software from products intended to provide clinical diagnostic results. Merely describing a diagnostic product as research software does not necessarily remove it from regulation if its actual intended purpose is medical diagnosis.

6. RELEVANT JUDICIAL DECISIONS

The following cases establish relevant principles of medical-device responsibility, informed consent, privacy, and professional negligence. They are analogous authorities rather than decisions specifically concerning genomic software.

1. Samira Kohli v. Dr. Prabha Manchanda (2008) – Directly relevant to informed consent

The Supreme Court of India emphasised that medical procedures generally require voluntary and informed consent. This principle is relevant when genomic software is used to guide consequential medical interventions or genetic testing.

2. Jacob Mathew v. State of Punjab (2005) – Analogous authority

The Supreme Court explained the legal standards governing medical negligence and professional responsibility. A healthcare professional relying on defective genomic software may face liability where the reliance falls below the applicable standard of care.

3. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017) – Direct constitutional authority on privacy

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms. Its principles are particularly important for protecting genomic information against unauthorised collection, disclosure, and misuse.

4. Indian Medical Association v. V.P. Shantha (1995) – Analogous authority

The Supreme Court considered the application of consumer-protection principles to medical services. The decision provides a foundation for examining consumer remedies arising from deficient healthcare services involving genomic diagnostic software.

5. Spring Meadows Hospital v. Harjol Ahluwalia (1998) – Analogous authority

The Supreme Court addressed medical negligence and the responsibility of healthcare institutions. Its principles may apply where hospitals negligently deploy, supervise, or rely upon defective diagnostic software.

6. A.S. Mittal v. State of Uttar Pradesh (1989) – Analogous authority

The Supreme Court considered negligence and responsibility arising from a medical eye-treatment camp. The decision is relevant to institutional responsibility and the duty to maintain appropriate standards of patient safety when deploying medical technologies.

7. Common Cause v. Union of India (2018) – Analogous constitutional authority

The Supreme Court recognised important principles of individual autonomy and dignity in medical decision-making. These principles support patient control over consequential medical decisions informed by genetic predictions.

7. LIABILITY AND REGULATORY ENFORCEMENT

Different parties may incur legal responsibility depending on their roles and conduct.

A. MANUFACTURERS: May face regulatory or civil liability for defective software, misleading performance claims, inadequate validation, and failure to comply with licensing requirements.

B. SOFTWARE DEVELOPERS: May incur contractual, professional, or other legal liability for negligent development, inadequate cybersecurity, or knowingly concealed defects.

C. HEALTHCARE PROVIDERS: May be responsible for negligent interpretation of genomic results, failure to verify clinically significant findings, or inappropriate reliance on automated recommendations.

D. HOSPITALS AND LABORATORIES: Must maintain suitable procurement, validation, access-control, quality-assurance, and patient-safety procedures.

Regulatory authorities may take action against unauthorised manufacture, import, sale, or distribution and other violations of applicable medical-device legislation.

8. PRACTICAL COMPLIANCE REQUIREMENTS

Genomic medical-device software companies operating in India should:

Determine whether their software qualifies as a medical device or IVD.

Obtain the appropriate CDSCO licence or regulatory permission.

Establish analytical and clinical validation protocols.

Implement a documented quality-management system.

Maintain cybersecurity and software-update controls.

Protect patient genomic and identifiable health information.

Establish procedures for reporting adverse events and software defects.

Ensure that diagnostic claims are supported by scientific evidence.

Maintain audit trails and traceable software versions.

Conduct continuing post-market performance and safety monitoring.

9. CONCLUSION

Medical Device Software for Genomics Regulation Law is an important developing area of healthcare and biotechnology governance. Its purpose is to ensure that genomic diagnostic software, AI-based genetic interpretation systems, and sequencing applications are scientifically validated, clinically reliable, secure, and appropriately regulated before being used in patient care.

In India, the Drugs and Cosmetics Act, 1940, Medical Devices Rules, 2017, applicable IVD requirements, data-protection legislation, and constitutional principles collectively provide the principal regulatory foundation. Effective enforcement, transparent clinical validation, patient consent, cybersecurity, and accountability of manufacturers and healthcare institutions are essential to protect patients while encouraging responsible genomic innovation.